Alberta fourth province to expand access to SPINRAZA™ for patients impacted with Spinal Muscular Atrophy.
Muscular Dystrophy Canada (MDC) commends the Government of Alberta for joining Quebec, Saskatchewan, and Ontario in expanding access to SPINRAZA™, a life-changing treatment for individuals impacted with Spinal Muscular Atrophy (SMA).
In Alberta, the following patients will now be eligible for reimbursement of SPINRAZA™, in addition to Type 1 patients:
- patients who are pre-symptomatic with two or three copies of SMN2, or
- have had disease duration of less than six months, two copies of SMN2, and symptom onset the first week after birth and on or before seven months of age, or
- are under the age of 18 with symptom onset after six months of age, regardless of the ability to walk.
- Other patients who do not meet the expanded funding criteria may be considered in exceptional cases.